Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (October 25th Preview)
-
Policy: U.S. restricts new investment into Chinese biotech under COINS framework
The U.S. Treasury has proposed new restrictions on outbound investment tied to China’s biotech sector under the Comprehensive Outbound Investment National Security Act (COINS). The proposal would bar U.S. companies from entering certain financial transactions with Chinese biotech companies and biotechnology-related equipment manufacturers. The rule is aimed at national-security risk areas and would add biotechnology to a list that already includes sectors such as semiconductors, artificial intelligence, and quantum technology. The proposal is being framed as an implementation step for COINS, with the specific scope and timelines expected to be central to industry response. For biotech, the practical impact centers on dealmaking capacity—licensing, partnerships, and financing arrangements where exposure to Chinese biotech counterparties is required.
-
Transaction: Gilead to buy PepStar’s oral IL-23R inhibitor platform for $1.275B upfront
Gilead announced it will acquire global rights to PepStar Therapeutics’ oral IL-23R inhibitor program, HCXT-2001, paying $1.275 billion in upfront cash at closing. HCXT-2001 is currently in Phase I testing and is positioned as an oral, IL-23 pathway inhibition strategy for inflammatory bowel disease. The deal structure includes customary adjustments to the upfront payment and additional milestones tied to development and commercialization, plus royalties. Gilead framed the acquisition as an expansion of its inflammation and immunology pipeline, with stated interest in HCXT-2001 alone or combined with other assets such as emvistegrast. Industry watchpoints include whether the oral modality yields differentiation on efficacy and safety versus existing IL-23 inhibitors and how quickly the program moves from Phase I into later trials.
-
Clinical safety: Bristol Myers discloses death in autoimmune CAR-T trial
Bristol Myers Squibb reported a patient death in an early autoimmune CAR-T trial, citing septic pneumonia after new or worsened neurologic and inflammatory motor symptoms. The company said the patient did not recover after standard autoimmune treatments and subsequently received a potent immunosuppressant, with the fatal outcome following. The disclosure comes amid growing scrutiny of safety events across CAR-T programs directed at autoimmune indications. Bristol’s earlier pause in its program was linked to “transient and reversible inflammatory events,” and Novartis has also disclosed multiple deaths in related autoimmune CAR-T studies. For biotech developers, the episode underscores how quickly inflammation-management protocols and patient-selection criteria are becoming critical variables in next-generation cell therapies for non-malignant targets.
-
Oncology efficacy: Tango and Revolution combine to drive 82% response in advanced pancreatic cancer
Tango Therapeutics reported trial results showing an 82% tumor response rate with its investigational regimen in combination with Revolution Medicines’ Rasonque for advanced pancreatic cancer. In the reported dataset, 88% of patients remained alive without tumor progression at nine months, and the study highlights the absence of chemotherapy in the regimen. The announcement positions the strategy as an example where targeted combinations may outperform single-agent approaches in tough-to-treat subtypes of pancreatic cancer. The readout was framed as bolstering a development path focused on better outcomes without traditional chemotherapy sequencing. The next steps for the field will likely center on confirmatory trials and on identifying the molecular or clinical factors that predict durable disease control within the responders.
-
Oncology dealmaking: Zymeworks licenses trispecific DLL3 T cell engager to Roche for up to $813M
Roche has entered a global licensing and collaboration agreement with Zymeworks for ZW209, a trispecific T-cell engager targeting DLL3. Zymeworks will receive $55 million upfront, with an additional $40 million upon Phase Ib initiation, and eligibility for up to $718 million in further milestone payments plus tiered royalties. ZW209 is designed to engage T cells via CD3 and CD28 while targeting DLL3-expressing tumor cells, with conditional CD28 engagement and obligate cis-binding intended to reduce unintended T-cell activation. Zymeworks said the FDA has cleared the investigational new drug application for ZW209. For biotech and pharma strategists, the agreement is a signal of continuing expansion in multispecific cell-engager modalities, and it adds a new potential competitor to the DLL3-targeted landscape.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.